Study of VIP152, Venetoclax, and Prednisone (VVIP) in Relapsed/Refractory Lymphoid Malignancies
NCT05371054
DESCRIPTION OF STUDY
Vincerx has partnered with the National Institutes of Health for this Phase 1 dose-escalation study. The purpose of the study is to determine the maximum tolerated dose, recommended Phase 2 dose, and the safety and toxicity of the combination of enitociclib with venetoclax and prednisone (VVIP).
ELIGIBILITY
- Age: 18+
- Sex: Both
- Status: Recruiting